Equities research analysts at Roth Capital initiated coverage on shares of Cogentix Medical, Inc. (NASDAQ:CGNT) in a note issued to investors on Wednesday, November 8th, MarketBeat.com reports. The brokerage set a “buy” rating and a $4.00 price target on the medical device company’s stock. Roth Capital’s price target suggests a potential upside of 40.35% from the company’s current price.
Several other equities analysts have also commented on the company. JMP Securities began coverage on Cogentix Medical in a research note on Friday, October 6th. They issued an “outperform” rating and a $5.00 target price for the company. Zacks Investment Research upgraded Cogentix Medical from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Friday, August 4th.
Shares of Cogentix Medical (NASDAQ:CGNT) opened at $2.85 on Wednesday. Cogentix Medical has a 12-month low of $1.55 and a 12-month high of $3.26.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with our FREE daily email newsletter.